In VivoThe 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
ScripThe 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
ScripArtificial intelligence-focused biotech Isomorphic Labs is getting another big infusion of funding to further develop its drug-design system and also to advance some of its programs into the clinic, o
In VivoArtificial intelligence was more than a buzzword in 2024; it shaped pharmaceutical industry investments throughout the year, with multiple billion-dollar partnerships and acquisitions across the drug